Glossary

  1. A

    ADC
    Antibody drug conjugate; a tumor growth-inhibiting substance (cytostatic) that is coupled to an antibody to attack tumors in an even more targeted manner
    ADCC
    Antibody-dependent cell-mediated cytotoxicity; a mechanism of cell-mediated immunity whereby an effector cell of the ­immune system actively destroys a target cell that has been bound by specific antibodies
    ADCP
    Antibody-dependent cellular phagocytosis
    ALL
    Acute lymphoblastic leukemia; a form of cancer of the white blood cells characterized by excess lymphoblasts
    Antibody
    Proteins of the immune system that ­recognize antigens, thereby triggering an immune response
    Antibody library
    A collection of genes that encode corresponding human antibodies
    Antigen
    Foreign substance stimulating ­antibody production; binding partner of antibody
    Autoimmune disease
    Disease caused by an immune response by the body against one of its own tissues, cells or molecules
  2. B

    B-ALL
    acute lymphoblastic B cell leukemia, blood cancer affecting white blood cells, subform of ALL
    B cells
    white blood cells, part of the immune system, capable of generation antibodies
    B-MIND
    Study to evaluate Bendamustine-MOR208 IN DLBCL
    Biosimilars
    Term used to describe officially approved new versions of innovator biopharmaceutical products, following patent expiration
    Bispecific
    Antibody consisting of parts from two different antibodies
  3. C

    CAR-T technology
    New therapeutic approach in which immune cells are reprogrammed
    Cash flow
    Key performance indicator in the cash flow statement used to assess the financial and earning capacity
    CD3
    surface antigen on T cells
    CD19
    Therapeutic target for the treatment of B cell lymphomas and leukemias
    CD20
    Therapeutic target for the ­treatment of B cell lymphomas and ­leukemias
    CD38
    Therapeutic target for the treatment of multiple myeloma and certain leukemias
    Clinical trial
    Clinical trials allow ­safety and efficacy data to be collected for new drugs or devices; depending on the type of product and the stage of its development, investigators enroll healthy volunteers and/or patients into small pilot studies initially, followed by larger-scale studies in patients
    CLL
    Chronic lymphocytic leukemia; most common type of cancer of the blood and bone marrow, affecting the B cells
    CMO
    Contract manufacturing organization
    COPD
    Chronic obstructive pulmonary disease
    COSMOS
    CLL patients assessed for ORR /Safety in MOR208 Study
    CR
    Complete response
    CRO
    Contract research organization
    CTO
    Contract testing organization
  4. D

    Diabetic nephropathy
    Kidney disease due to diabetes mellitus
    Discounted cash flow model
    Method of valuing assets, especially for due diligence
    DLBCL
    diffuse large B cell lymphoma, a subform of NHL
    DoR
    duration of response
  5. E

    EGFR
    Epidermal growth factor receptor; cell-surface receptor for members of the epidermal growth factor family (EGF-family) of extracellular protein ligands; the epidermal growth factor receptor is a receptor tyrosine kinase
    EMA
    European Medicines Agency
  6. F

    Fab format
    The antigen binding fragment of the antibody
    Fc part
    Constant part of an antibody known as the Fc (fragment, crystallizable) region
    FDA
    Food and Drug Administration; US ­federal agency for the supervision of food and drugs
    FL
    follicular lymphoma, a subform of NHL
  7. G

    GCP
    Good clinical practice; an inter­national ethical and scientific quality standard for ­designing, conducting, recording and reporting trials that involve the participation of ­human subjects
    GLP
    Good laboratory practice; a formal framework for the implementation of safety tests on chemical products
    GM-CSF
    Granulocyte-macrophage colony-stimulating factor; underlying target molecule of MOR103 program
    GMP
    Good management practice; term for the control and management of manufacturing and quality control testing of pharmaceutical products and medical devices
  8. H

    HuCAL
    Human Combinatorial Antibody ­Library; proprietary antibody ­library enabling rapid generation of ­specific human antibodies for all ­applications
    Human
    Of human origin
  9. I

    IFRS
    International Financial Reporting Standards; accounting standards issued by the IASB and adopted by the EU
    Immuno-oncology
    new class of compounds that stimulate the immune system to attack tumors
    Inclusion body myositis
    body myositis – Inflammatory muscle disease
    Innovation capital
    Investments in start-ups with technologies and product candidates being close to MorphoSys’s areas of interest
  10. L

    Lanthipeptides
    Novel class of therapeutics with high target selectivity and improved drug-like properties
    L-MIND
    Study to evaluate Lanalidomide-MOR208 IN DLBCL
  11. M

    Market capitalization
    Value of a com­pany’s outstanding shares, as measured by shares times current price
    MCL
    Mantle cell lymphoma, a subform of NHL
    mCRPC
    metastatic castration-resistant prostate cancer
    Mesothelioma
    Diffusely growing tissue tumor affecting for example the pleura
    Monoclonal antibody
    Homogeneous antibody originating from a single clone, produced by a hybridoma cell
    multiple myeloma
    Type of cancer that develops in a subset of white blood cells called plasma cells formed in the bone marrow
  12. N

    Nasdaq Biotechnology Index
    stock market index made up of biotechnological or pharmaceutical companies listed at the US stock exchange NASDAQ
    NHL
    Non-Hodgkin lymphomas; diverse group of blood cancers that include any kind of lymphoma ­except Hodgkin’s lymphomas
    NK cells
    Natural killer cells of the body’s immune system; cells capable of recognizing and killing abnormal cells, e.g. tumor cells
  13. O

    ORR
    Overall response rate
    OS
    Overall survival
  14. P

    Palmoplantar pustulosis
    Psoriasis on hands and feet
    Pediatric study
    A study conducted in the area of children and adolescent medicine
    PFS
    Progression-free survival
    Pharmacodynamics
    Study of the effects of drugs on the body
    Pharmacokinetics
    Determination of the fate of substances administered externally to a living ­organism
    PR
    Partial response
    Preclinic
    Preclinical stage of drug development; tests in animal models as well as in laboratory essays
    Protein
    Polymer consisting of amino acids, e. g. antibodies and enzymes
    Psoriasis
    A chronic, non-contagious autoimmune disease which affects the skin and joints
    Psoriatic arthritis (PsA)
    Chronic joint inflammation that occures in connection with psoriasis
  15. R

    Rheumatoid arthritis
    Inflammatory disease of the joints; abbreviation: RA
    Royalties
    Percentage share of ownership of the revenue generated by drug products
  16. S

    Scaffolds
    Proteins with antibody - like ­capabilities
    sIBM
    sporadic inclusion body myositis, inflammatory myopathy
    SLL
    Small lymphocytic lymphoma
    Slonomics
    DNA engineering and protein library generation platform acquired by MorphoSys in 2010
    Small molecules
    Low molecular compounds
    SOP system
    SOP = standard operating procedure
  17. T

    Target
    Target molecule for thera­peutic intervention, e.g. on the surface of diseased cells
    Target molecule selectivity
    Criteria to describe to what degree an antibody binds to other structures besides its target molecule
    Target product profile (TPP)
    Summary of specifications on a planned therapeutic product
    T cells
    An abbreviation for T-lymphocytes; a subtype of white blood cells that together with B-lymphocytes are responsible for the body’s immune defense
    TecDAX
    Index of the 30 largest ­technology companies listed on the Frankfurt Stock Exchange
    TTP
    Time to progression
    Toxicity
    Poisonousness
  18. Y

    Ylanthia
    The novel next-generation antibody platform of MorphoSys
arrow-topCreated with sketchtool.Top arrow-leftCreated with sketchtool.Financial Calendar